Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2020

01-12-2020 | NSCLC | Research article

LncRNA FEZF1-AS1 promotes non-small lung cancer cell migration and invasion through the up-regulation of NOTCH1 by serving as a sponge of miR-34a

Authors: Shangxiao Huang, Chunjun Li, Jianfeng Huang, Penghui Luo, Dunchang Mo, Hanlei Wang

Published in: BMC Pulmonary Medicine | Issue 1/2020

Login to get access

Abstract

Background

The involvement of lncRNA FEZF1-AS1 has been analyzed in many types of cancers, while its roles in non-small cell lung cancer (NSCLC) remains unclear. We then explored the role of FEZF1-AS1 in NSCLC.

Methods

qPCR and western blot were performed to measure gene expression. FEZF1-AS1, miR-34a, and NOTCH-1 were overexpressed to analyze the relationship between them. Transwell assays were performed to analyze the effects of transfections on cell invasion and migration.

Results

FEZF1-AS1 was up-regulated in NSCLC patients. Increased expression levels of FEZF1-AS1 were observed with the increase in clinical stages. Bioinformatics analysis showed that miR-34a can bind with FEZF1-AS1. In NSCLC tissues, NOTCH-1 and FEZF1-AS1 were positively correlated. In NSCLC cells, over-expression of FEZF1-AS1 resulted in up-regulated expressions of NOTCH-1, while miR-34a over-expression mediated down-regulated expressions of NOTCH-1. In addition, FEZF1-AS1 and miR-34a did not alter each other, while bioinformatics analysis showed that miR-34a can bind FEZF1-AS1. Analysis of cell migration and invasion showed increased cell invasion and migration rates after FEZF1-AS1 and NOTCH-1 over-expression. MiR-34a played the opposite role and reduced the effects of FEZF1-AS1 over-expression.

Conclusions

FEZF1-AS1 promoted NSCLC cell migration and invasion through the up-regulation of NOTCH1 by serving as a sponge of miR-34a.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMed Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMed
2.
3.
go back to reference Torre LA, Siegel RL, Jemal A. Lung cancer statistics [M]//lung cancer and personalized medicine. Cham: Springer; 2016. p. 1–19.CrossRef Torre LA, Siegel RL, Jemal A. Lung cancer statistics [M]//lung cancer and personalized medicine. Cham: Springer; 2016. p. 1–19.CrossRef
4.
go back to reference Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non–small-cell lung cancer. N Engl J Med. 2017;376(22):2109–21.PubMedCrossRef Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non–small-cell lung cancer. N Engl J Med. 2017;376(22):2109–21.PubMedCrossRef
5.
go back to reference Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.PubMedCrossRef Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.PubMedCrossRef
6.
go back to reference Jung KW, Won YJ, Oh CM, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49(2):292–305.PubMedPubMedCentralCrossRef Jung KW, Won YJ, Oh CM, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49(2):292–305.PubMedPubMedCentralCrossRef
7.
go back to reference Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015;4(4):327–38.PubMedPubMedCentral Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015;4(4):327–38.PubMedPubMedCentral
8.
go back to reference Gazdar AF, Zhou C. Lung cancer in never-smokers: a different disease [M]//IASLC Thoracic Oncology. Cont Repository Only. 2018:23–9 e3. Gazdar AF, Zhou C. Lung cancer in never-smokers: a different disease [M]//IASLC Thoracic Oncology. Cont Repository Only. 2018:23–9 e3.
9.
go back to reference Cooper WA. Molecular genetics of non-small cell lung cancer–current state of play. Pathology. 2016;48:S10.CrossRef Cooper WA. Molecular genetics of non-small cell lung cancer–current state of play. Pathology. 2016;48:S10.CrossRef
10.
go back to reference Fender AW, Nutter JM, Fitzgerald TL, et al. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. J Cell Biochem. 2015;116(11):2517–27.PubMedCrossRef Fender AW, Nutter JM, Fitzgerald TL, et al. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. J Cell Biochem. 2015;116(11):2517–27.PubMedCrossRef
11.
go back to reference Shao S, Zhao X, Zhang X, et al. Notch1 signaling regulates the epithelial–mesenchymal transition and invasion of breast cancer in a slug-dependent manner. Mol Cancer. 2015;14(1):28.PubMedPubMedCentralCrossRef Shao S, Zhao X, Zhang X, et al. Notch1 signaling regulates the epithelial–mesenchymal transition and invasion of breast cancer in a slug-dependent manner. Mol Cancer. 2015;14(1):28.PubMedPubMedCentralCrossRef
12.
13.
go back to reference Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA–lncRNA interactions [M]//long non-coding RNAs. New York: Humana Press; 2016. p. 271–86. Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA–lncRNA interactions [M]//long non-coding RNAs. New York: Humana Press; 2016. p. 271–86.
14.
go back to reference Bian Z, Zhang J, Li M, et al. LncRNA–FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal Cancer by regulating PKM2 signaling. Clin Cancer Res. 2018;24(19):4808–19.PubMedCrossRef Bian Z, Zhang J, Li M, et al. LncRNA–FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal Cancer by regulating PKM2 signaling. Clin Cancer Res. 2018;24(19):4808–19.PubMedCrossRef
15.
go back to reference He R, Hu Zhang F, Shen N. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC). Biomed Pharmacother. 2017;95:331–8.PubMedCrossRef He R, Hu Zhang F, Shen N. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC). Biomed Pharmacother. 2017;95:331–8.PubMedCrossRef
16.
go back to reference Li Q, Chen L, Hu N, et al. Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis. Biomed Pharmacother. 2018;103:1727–32.PubMedCrossRef Li Q, Chen L, Hu N, et al. Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis. Biomed Pharmacother. 2018;103:1727–32.PubMedCrossRef
Metadata
Title
LncRNA FEZF1-AS1 promotes non-small lung cancer cell migration and invasion through the up-regulation of NOTCH1 by serving as a sponge of miR-34a
Authors
Shangxiao Huang
Chunjun Li
Jianfeng Huang
Penghui Luo
Dunchang Mo
Hanlei Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2020
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-020-1154-6

Other articles of this Issue 1/2020

BMC Pulmonary Medicine 1/2020 Go to the issue